A rare side effect of entecavir : hepatomegaly and steatosis
Yükleniyor...
Dosyalar
Tarih
2017
Yazarlar
Dergi Başlığı
Dergi ISSN
Cilt Başlığı
Yayıncı
Erişim Hakkı
info:eu-repo/semantics/openAccess
Özet
Hepatomegali ve steatoz nükleozid analoglarının nadir görülen ancak fatal seyredebilen bir yan etkisidir. Bu olgu sunumunda 5 yıl süre ile entekavir tedavisi almakta olan 53 yaşında erkek hastada hepatomegali ve steatoz gelişimi sunulmuştur. Hastada entekavir tedavisi sırasında laktik asidoz bulgusu olmaksızın progresif hepatomegali ve steatoz gelişmiştir. Entekavir tedavisi tenofovir ile değiştirildikten 3 ay sonra karaciğer boyutu normalleşmiş ve tenofovir tedavisinin ilk 3 yılında normal aralıkta seyretmiştir. Bu nedenle, hepatomegali ve steatozun entekavir tedavisine bağlı gelişmiş olması muhtemeldir. Nükleozid analoglarının neden olduğu hepatomegali ve steatoz nadirdir ve bildirilen olguların çoğunda laktik asidoz ile ilişkilidir. Bildiğimiz kadarıyla daha önce entekavir tedavisine sekonder, laktik asidoz bulgusu olmaksızın gelişen hepatomegali ve steatoz olgusu bildirilmemiştir. Bu olgu sunumunun amacı entekavirin nadir görülen bir yan etkisini ortaya koymak ve uygulanan tedavi yaklaşımını paylaşmaktır
Hepatomegaly and steatosis are rare but potentially fatal side-effects of nucleoside analogues. Here, we present the case of development of hepatomegaly and steatosis in a 53-year-old male who had been treated with entecavir for five years. There were no symptoms of lactic acidosis. At three months after changing entecavir to tenofovir, the liver size returned to normal and maintained within the normal range during the 3-year follow-up. Therefore, it can be presumed that the hepatomegaly and steatosis were due to entecavir therapy. There are very few reports of hepatomegaly and steatosis caused by nucleoside analogues and the majority of the reported cases were associated with lactic acidosis. To the best of our knowledge, there are no previously reported cases of hepatomegaly and steatosis due to entecavir therapy without evidence of lactic acidosis. The aim of this clinical report was to point out a rare side-effect of entecavir and to share our treatment approach
Hepatomegaly and steatosis are rare but potentially fatal side-effects of nucleoside analogues. Here, we present the case of development of hepatomegaly and steatosis in a 53-year-old male who had been treated with entecavir for five years. There were no symptoms of lactic acidosis. At three months after changing entecavir to tenofovir, the liver size returned to normal and maintained within the normal range during the 3-year follow-up. Therefore, it can be presumed that the hepatomegaly and steatosis were due to entecavir therapy. There are very few reports of hepatomegaly and steatosis caused by nucleoside analogues and the majority of the reported cases were associated with lactic acidosis. To the best of our knowledge, there are no previously reported cases of hepatomegaly and steatosis due to entecavir therapy without evidence of lactic acidosis. The aim of this clinical report was to point out a rare side-effect of entecavir and to share our treatment approach
Açıklama
Anahtar Kelimeler
Gastroenteroloji ve Hepatoloji
Kaynak
Viral Hepatitis Journal
WoS Q Değeri
Scopus Q Değeri
Cilt
23
Sayı
3
